Vancouver-based Absci marks major milestone in partnership with ...
1 day ago · The company reported Tuesday it brought in $1.7 million in its third quarter of 2024, up from $700,000 in the third quarter of 2023. It also reported a $27.4 million net loss, 24 cents per diluted ...
Absci Reports Business Updates and Third Quarter 2024 Financial …
2 days ago · Absci continues to advance ABS-101 through IND-enabling studies, plans to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025, and continues to expect an interim data readout ...
Absci Corp (ABSI) Q3 2024 Earnings Call Highlights: Strategic ...
1 day ago · Revenue: $1.7 million for Q3 2024. Research and Development Expenses: $18 million for Q3 2024, up from $11 million in the prior year period. Selling, General, and Administrative Expenses: $9.3 ...
Absci Reports Business Updates and Third Quarter 2024 Financial …
2 days ago · Absci will host a conference call to discuss its third quarter 2024 business updates and financial and operating results on Tuesday, November 12, 2024 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific ...
Absci Reports Business Updates and Third Quarter 2024 Financial …
2 days ago · Absci anticipates completion of mode-of-action validation studies for this program in the first half of 2025. Additional Internal Pipeline Programs: In addition to further development of ABS-101, ABS-201, and ABS-301, Absci expects to advance at least one additional internal asset program to a lead stage in 2024.
News releases - Absci Corp
Absci is a data-first generative AI drug creation company that reports quarterly financial and operating results and participates in investor conferences. See the latest news on its pipeline, collaborations, and stock performance.
Absci Corporation Advances AI-Driven Drug Development
1 day ago · Absci Corp. ( (ABSI)) has released its Q3 earnings. Here is a breakdown of the information Absci Corp. presented to its investors. Absci Corporation, a data-first generative AI drug creation ...
Q3 2024 Absci Corp Earnings Call - Yahoo Finance
2 days ago · Alexander Khan. Thank you. Earlier today, Absci released financial and operating results for the quarter ended September 30 2024. If you haven't received this news release or if you would like to ...
News Release Details - Absci Corp
Mar 21, 2024 · Absci reports business updates and financial results for Q4 and FY 2023, including partnerships, pipeline progress, and cash position. Absci is a data-first generative AI drug creation company that designs and develops potential best-in-class and first-in-class biologics.
Absci Announces Collaboration with AstraZeneca to Advance AI …
Vancouver, WA, December 4, 2023 – Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, today announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target.
- Some results have been removed